/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

D

Douglas E. Feltner

Exicure (United States)(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

112

Papers

6.4K

Citations

32

h-index

47

i10-index

Douglas E. Feltner is an academic researcher from Exicure (United States). The author has contributed to research in topics: Neurogenetic and Muscular Disorders Research & Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes & RNA modifications and cancer. The author has an h-index of 32, co-authored 96 publications.

Research Topics

Neurogenetic and Muscular Disorders Research Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes RNA modifications and cancer Child and Adolescent Psychosocial and Emotional Development Treatment of Major Depression

Papers by this author

works

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

2021 · The Lancet Neurology · 449 citations

https://doi.org/10.1016/s1474-4422(21)00001-6

John Day Richard S. Finkel Claudia A. Chiriboga Anne M. Connolly

Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial

2003 · American Journal of Psychiatry · 315 citations

https://doi.org/10.1176/appi.ajp.160.3.533

Atul C. Pande Jerri G. Crockatt Douglas E. Feltner Carol A. Janney

Psychometric evaluation of a visual analog scale for the assessment of anxiety

2010 · Health and Quality of Life Outcomes · 271 citations

https://doi.org/10.1186/1477-7525-8-57

Valerie Williams Robert Morlock Douglas E. Feltner

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study of Pregabalin in Patients With Generalized Anxiety Disorder

2003 · Journal of Clinical Psychopharmacology · 259 citations

https://doi.org/10.1097/01.jcp.0000084032.22282.ff

Douglas E. Feltner Jerri G. Crockatt Steven J. Dubovsky Cal K. Cohn

A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH <sub>1</sub> Antagonist) in the Treatment of Major Depression

2008 · American Journal of Psychiatry · 248 citations

https://doi.org/10.1176/appi.ajp.2008.07071199

Brendon Binneman Douglas E. Feltner Sheela Kolluri Yuanjun Shi

AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort

2019 · Journal of Neuromuscular Diseases · 176 citations

https://doi.org/10.3233/jnd-190403

Samiah Al-Zaidy Stephen J. Kolb Linda Lowes Lindsay N. Alfano

Research topics

topics

Neurogenetic and Muscular Disorders Research

Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes

RNA modifications and cancer

Child and Adolescent Psychosocial and Emotional Development

Treatment of Major Depression

Chat about Author

Papers

Chat

Click to start Chat